Stockreport

Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy

Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. [Read more]